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Objectives: The control of low-density lipoprotein cholesterol (LDLc) level using
lipid-lowering drugs (LLD) is an important secondary prevention of acute coronary
syndrome (ACS). We aimed at evaluating such secondary prevention in the newly-
onset ACS patients who underwent revascularization in Hong Kong. Methods: It was
a multi-centered, non-interventional, secondary cohort analysis of newly-onset ACS
Chinese patients who were statin-naive and underwent revascularization from 2004
to 2017 (N=2351). In addition to yearly descriptive statistics, LLD utilization and LDLc
attainment were evaluated for 5 consecutive years following the first revasculari-
zation, supplemented with a monetary descriptive estimation of the relevant direct
medical costs. Results: The LDLc attainment had gradually improved over the years,
accompanied with an increasing LLD usage, majority being moderate and low in-
tensity statin monotherapy. However, there was a severe and clinically inappropriate
delay in giving LLD after the first revascularization (median = 8 months). In the same
month of the first revascularization (i.e. month 1), 86.3% (2029/2351) of patients
received no LLD. After excluding statin-associated side effects (12.4%), abnormal
alanine transaminase (3%) and creatinine kinase (2.8%), still around 68.1% had no LLD
prescribed with unknown reasons. Such prescribing practice even extended to
month 1-6, 7-12 and had persisted throughout the 13 years. Only 22.2% (480/2162)
were on LLD and with at least 1 lipid test in the first year. Moreover, the monetary
descriptive estimation revealed that prompt and continuous use of LLD upon the first
revascularization could significantly lower the total direct medical costs for 5
consecutive follow-up years. Conclusions: Severe underuse of LLD and insufficient
lipid test, particularly in the first year after the first revascularization, were evident
and persistent in the newly-onset ACS patients in Hong Kong.
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Objectives: Cardiovascular disease remains the leading cause of death in Portugal
and across the world. Atherosclerosis is the most common pathophysiologic pro-
cess underlying CVD. Its clinical manifestations include coronary artery disease
(CAD), cerebrovascular disease (CVD) and peripheral artery disease (PAD). This
study aims to determine the clinical and demographic characteristics of adult pa-
tients with atherosclerosis in a Portuguese primary care comprehensive adminis-
trative database. Methods: Population-based study with real data from a large health
region in Portugal with a population of 3.6 million. The data covers patients attending
primary care services in 2016 and eligible patients included adults with at least one GP
visit in 2016. Patients were selected for inclusion by fulfilling at least one of the
following criteria: diagnosis for clinical manifestations (CAD, CVD or PAD), dispensing
of antiplatelet drugs or peripheral vasodilators or the presence of at least three car-
diovascular risk factors. These criteria were used as a proxy for atherosclerosis (either
clinical or subclinical), since some patients might be either not diagnosed or the
condition not registered. We analyzed patients’ characteristics, comorbidities and
resource use in 2016. Results: We identified 318,692 patients that that fulfilled at least
one of the criteria for atherosclerosis. About half of these (155,312) had at least three
cardiovascular risk factors without mention of clinical manifestations. Among those
with clinical manifestations (93,847), CAD was the most common (52%). Patients with
atherosclerosis are mostly women (51%) and on average 72611 years old. Common
comorbidities were hypertension (75%), dyslipidemia (54%) and diabetes (41%). During
the year 73% had at least one cardiovascular medical test or diagnostic procedure
done; almost all patients had at least one cardiovascular medication dispensed. The
average number of GP visits were 4 per patient. Conclusions: Atherosclerosis, either
clinical or subclinical, is common in primary care users in Portugal. CAD is the most
frequent clinical manifestation.
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Objectives: Randomized placebo-controlled trials with Ferric Carboxymaltose
(FCM) have shown a clinical benefit in the correction of iron deficiency (ID) in
patients with Chronic Heart Failure (CHF). FCM is associated with significant
improvements in functional capacity, symptoms and quality of life. Reduction in
the risk of first hospitalization and recurrent hospitalization due to worsening
heart failure were also identified. The aim of this study is to investigate if FCM
therapy could be associated with a reduction of recurrent hospital admissions and
ambulatory visits in routine clinical practice. A hospital registry in the
Spanish NHS is used to analyze retrospectively data from 1,498 CHF patients.
Methods: The hospital registry provides information of 1,498 patients (10,522
observations) from 2010 to 2019 with an average follow-up period of 4.02 years.
The registry allows the extraction and analysis of data related to demographic and
clinical characteristics, laboratory tests and healthcare resource use of two co-
horts of CHF patients with ID: 317 patients who received intravenous iron-
replacement therapy with FCM and 1,181 patients who did not receive FCM. The
statistical method used was multilevel negative binomial regression with random
intercept on patient ID and time follow-up as offset. Results: The incidence rate
of iron deficiency in the whole sample was 0.488 events per person-year. Treat-
ment with FCM was strongly associated with a decrease in the rate of recurrent
hospitalizations (IRR = 0.25, 95% CI 0.15-0.44; P ,0.001), even after controlling for
age, gender, diabetes, HF-ethiology, ferritin and TSAT. In addition, and compared
to patients who received FCM, those with no treatment with FCM showed higher
risk of ambulatory visits (IRR = 2.08, 95% CI 1.90-2.27; P ,0.001) Con-
clusions: This study shows that intravenous FCM is associated with a reduction in
recurrent hospitalizations and ambulatory visits for patients with iron deficiency
and CHF in routine clinical practice.
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Objectives: Sacubitril/valsartan is indicated in adult patients with symptomatic
heart failure with reduced ejection fraction. According to its posology, dose
should be doubled at 2-4 weeks to the target dose. However, previous real-world
studies have reported slow titration schemes. The objective of this analysis was to
evaluate sacubitril/valsartan prescription and titration patterns in a real-world
setting in Portugal. Methods: The PRiMe study is a cross-sectional and multi-
center study. Adult patients ($18 years) or caregivers with a prescription (initial
or refill) of sacubitril/valsartan were recruited through Portuguese community
pharmacies. A structured questionnaire was applied to collect data directly from
the patients or caregivers with support from a trained pharmacist. Additional data
were collected through the pharmacy’s software and patient’s echocardiogram
report. Results: As of May 2019, 262 eligible patients (27.6% starting sacubitril/val-
sartan for the first time) were recruited. The first prescription of sacubitril/valsartan
was in 82.3% of the patients filled in by a cardiologist, 9.3% by a general practitioner
(GP) and 6.8% by an internist. In the majority of cases (72.9%), sacubitril/valsartan
initiation started after a programmed medical appointment and in 25.9% after an
emergency/hospitalization episode. Among refills, cardiologists were responsible for
48.1% of refills, GPs for 36.1% and internists for 12.8%. A total of 42.1%, 32.4% and 6.0% of
the patients started sacubitril/valsartan 24 mg/26 mg, 49 mg/51 mg and 97 mg/103
mg, twice daily, respectively. After a mean time of 4.9 months (SD=3.9) of sacubitril/
valsartan treatment, 31.3% were taking the 24 mg/26 mg dose, 36.5% the 49 mg/51 mg
dose and 17.4% the 97 mg/103 mg dose, twice daily. A total of 60.9% patients did not
change doses while 31.3% had at least one uptitration. Conclusions: In a real-world
setting, the uptitration of sacubitril/valsartan is slow, if considered a mean of five
months treatment with sacubitril/valsartan.
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Objectives: Rivaroxaban, a direct oral anticoagulant (DOAC) targeting activated
coagulation factor X (FXa), reduces the risk of stroke or systemic embolism in pa-
tients with nonvalvular atrial fibrillation and one or more risk factors for stroke. The
aim of the study was to determine the prescribing patterns of rivaroxaban in a South
African private healthcare setting. Methods: A retrospective drug utilisation study
was conducted on a South African medical insurance administrator database for
2018. The database contained 4191138 records for medicine, medical devices and
procedures. All products in ATC group B01A (Antithrombotic agents) were analysed.
Results: A total of 32961 antithrombotic products were prescribed to 6036 patients
(54.04% male patients) at a total amount claimed of R4697585. The average age of
